Davunetide vs P21

Stabilizes microtubules by interacting with tubulin and microtubule-associated proteins. Activates SIRT1, reduces amyloid-β toxicity, and enhances synaptic plasticity. Protects against tau hyperphosphorylation.

Davunetide (AL-108; NAP; NAPVSIPQ) is a synthetic octapeptide derived from activity-dependent neuroprotective protein (ADNP), initially identified as a neuroprotective sequence from ADNP and investigated in clinical trials as a candidate treatment for cognitive impairment associated with schizophrenia and tauopathies including progressive supranuclear palsy. Davunetide is proposed to stabilize microtubule dynamics by interacting with tubulin and preventing tau hyperphosphorylation-related cytoskeletal disruption, and preclinical models demonstrated neuroprotective and procognitive effects at nanomolar concentrations. Clinical investigation included Phase 2 trials examining cognitive outcomes and MRS neuroimaging biomarkers in schizophrenia patients, and a Phase 2/3 trial in progressive supranuclear palsy; results showed some neurochemical effects but no consistent meaningful cognitive improvement across clinical endpoints, and the PSP program did not meet its primary outcomes. Davunetide has no FDA approval and no approved indication in any jurisdiction; clinical development has been discontinued following negative trial outcomes, and while its preclinical neuroprotective profile remains scientifically interesting, the clinical evidence does not establish efficacy for cognitive enhancement or neuroprotection in any condition.

Derived from CNTF; increases BDNF expression and promotes hippocampal neurogenesis; modulates PI3K/Akt pathway

P021 (also designated Peptide 6) is a synthetic tetrapeptide derived from the neurotrophic activity domain of ciliary neurotrophic factor (CNTF), developed to provide the neuroprotective and neurogenic actions of endogenous CNTF at small-molecule scale, with adamantane incorporation designed to improve oral bioavailability and CNS penetrance. It is proposed to upregulate BDNF and other neurotrophic factors through MAPK/ERK signaling pathways, promoting hippocampal neurogenesis, supporting synaptic plasticity, and reducing tau hyperphosphorylation in preclinical models of neurodegeneration. Rodent studies from the Iqbal laboratory at the NYS Institute for Basic Research have demonstrated that P021 improves learning and memory, promotes hippocampal neurogenesis, and reduces amyloid-β and tau pathological markers in transgenic mouse models of Alzheimer's disease. P021 is a research compound with no regulatory approval in any jurisdiction; all published evidence to date is from preclinical animal studies, and no human clinical trials have been registered or completed as of 2025. P21 as a CNTF-pathway peptide In the nootropic and cognitive peptide research context, P21 refers to a synthetic peptide analogue based on the ciliary neurotrophic factor (CNTF) receptor-binding domain, designed to activate CNTF signalling without the full-length protein's size limitations and potential inflammatory side effects associated with systemic CNTF administration. CNTF is a neuroprotective cytokine that promotes neuron survival, enhances BDNF production, and supports hippocampal plasticity — pathways relevant to learning, memory consolidation, and neuronal resilience. Research on P21 in rodent models has reported improved spatial learning and memory retention, reduced tau phosphorylation markers associated with neurodegeneration, and effects on hippocampal synaptic density. Clinical data is absent; all published evidence comes from preclinical animal studies. P21 is available as a research peptide from specialty vendors; it is not approved by any regulatory agency and has no established safety or dosing profile in humans. It is discussed within nootropic communities alongside semax, selank, and dihexa as a peptide with proposed neuroprotective and cognitive-enhancement mechanisms, though its evidence base is substantially thinner than those compounds.